journal
https://read.qxmd.com/read/38478015/m6a-reader-igf2bp1-reduces-the-sensitivity-of-nasopharyngeal-carcinoma-cells-to-taxol-by-upregulation-of-akt2
#1
JOURNAL ARTICLE
Chong Zhao, Fang Zhang, Yang Tian, Bingjie Tang, Jing Luo, Jianhui Zhang
Taxol is widely used in the treatment of nasopharyngeal carcinoma (NPC); nevertheless, the acquired resistance of NPC to Taxol remains one of the major obstacles in clinical treatment. In this study, we aimed to investigate the role and mechanism of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in Taxol resistance of NPC. Taxol-resistant NPC cell lines were established by exposing to gradually increased concentration of Taxol. Relative mRNA and protein levels were tested using qRT-PCR and western blot, respectively...
March 12, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38477942/hoxa1-silencing-inhibits-cisplatin-resistance-of-oral-squamous-cell-carcinoma-cells-via-i%C3%AE%C2%BAb-nf-%C3%AE%C2%BAb-signaling-pathway
#2
JOURNAL ARTICLE
Ruifeng Zhu, Yiting Mao, Xianzhi Xu, Yingying Li, Jiwei Zheng
The resistance of oral squamous cell carcinoma (OSCC) cells to cisplatin remains a tough nut to crack in OSCC therapy. Homeobox A1 (HOXA1) overexpression has been detected in head and neck squamous carcinoma (HNSC). Accordingly, this study aims to explore the potential role and mechanism of HOXA1 on cisplatin resistance in OSCC. The expression of HOXA1 in HNSC and its role in overall survival (OS) rate of OSCC patients were analyzed by bioinformatic analysis. Following transfection as needed, OSCC cells were induced by different concentrations of cisplatin, and the cell viability and apoptosis were evaluated by cell counting kit-8 and flow cytometry assays...
March 12, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38453158/successful-treatment-with-selpercatinib-after-pralsetinib-related-pneumonitis-and-intracranial-failure-in-a-patient-with-ret-rearranged-nonsmall-cell-lung-cancer
#3
JOURNAL ARTICLE
Valeria Cognigni, Giulia Claire Giudice, Francesca Bozzetti, Gianluca Milanese, Ilaria Moschini, Miriam Casali, Giulia Mazzaschi, Marcello Tiseo
Pralsetinib and selpercatinib are two highly potent and selective rearranged during transfection (RET) inhibitors that substantially improved the clinical outcome of patients with RET-rearranged non-small cell lung cancer. Treatment with one RET inhibitor after failure of the other is generally not recommended because of cross-resistance mechanisms. We report the case of a patient affected by metastatic RET-rearranged non-small cell lung cancer who experienced long-lasting disease control with pralsetinib. After 13 months from treatment start, the patient developed recurrent drug-related pneumonitis, requiring temporary interruptions and dose reductions and eventually failing to control the disease...
March 8, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38453157/experience-with-pembrolizumab-in-a-renal-transplant-patient-with-advanced-lung-cancer-a-case-report-and-review
#4
JOURNAL ARTICLE
Laura Fernández Madrigal, Victoria García Samblás, Laura Sánchez Escudero
The treatment of non-small cell lung cancer (NSCLC) has undergone a change because of the advancement of new therapies, like immune checkpoint inhibitors (ICIs), including pembrolizumab. A 64-year-old woman received a kidney transplant in 2012 because of chronic kidney disease secondary to glomerulosclerosis, diagnosed in 2020 with stage IV NSCLC because of metastasis in the contralateral lung, with programmed death ligand 1programmed death ligand 1 expression of 98%, starting treatment with ICIs, despite presenting a graft rejection risk around 40%...
March 8, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38453155/delayed-cardiotoxicity-following-osimertinib-therapy-in-non-small-cell-lung-cancer-a-unique-case-report
#5
JOURNAL ARTICLE
Zhanwen Xu, Haiyan Jia, Xiaoping Yin
This case report features a 62-year-old male with stage IB lung adenocarcinoma harboring an epidermal growth factor receptor exon 19 deletion, who underwent treatment with osimertinib following a left upper lobectomy and lymph node dissection. Despite a history of smoking and well-managed type 2 diabetes, the patient developed heart failure 18 months post-initiation of osimertinib therapy, marking one of the latest occurrences of heart failure following osimertinib treatment documented in limited literature...
March 8, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38452059/a-phase-1-study-of-regorafenib-and-sildenafil-in-adults-with-advanced-solid-tumors
#6
JOURNAL ARTICLE
Andrew S Poklepovic, Sarah W Gordon, Sejal Kothadia, William P McGuire, Leroy R Thacker, Xiaoyan Deng, Mary Beth Tombes, Ellen Shrader, Daniel Hudson, Dipankar Bandyopadhyay, Alison A Ryan, Maciej Kmieciak, Steven Smith, Paul Dent
The purpose of this study is to establish the recommended phase 2 dose for regorafenib in combination with sildenafil for patients with advanced solid tumors. Secondary outcomes included identification of antitumor effects of regorafenib and sildenafil, toxicity of the combination, determination of PDE5 expression in tumor samples, and the impact of sildenafil on the pharmacokinetics of regorafenib. This study was a phase 1, open-label single-arm dose-escalation trial using a 3 + 3 design. Additional patients were enrolled at the maximum tolerated dose (MTD) until a total of 12 patients were treated at the MTD...
March 8, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38451831/concurrent-nras-braf-variants-in-metastatic-colorectal-cancer-a-tunisian-case-report
#7
JOURNAL ARTICLE
Hayet Douik, Ghada Sahraoui, Mohamed Jemaà, Raoudha Doghri, Lamia Charfi, Karima Mrad
Target therapy for metastatic colorectal cancer needs the determination of KRAS, NRAS, and BRAF mutation status to identify patients resistant to anti-EGFR treatment. RAS genes (KRAS/NRAS) are mutated in 40-60% of metastatic colorectal cancer and BRAF in 5-10%. The presence of a double mutation in RAS and BRAF is rare. Therefore, RAS and BRAF mutations were considered exclusive. Herein, we describe a novel concomitant NRAS/BRAF mutation identified in a series of 865 colorectal cancer patients.
March 5, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38451823/twelve-month-progression-free-survival-with-sotorasib-and-panitumumab-in-kras-g12c-mutant-metastatic-colorectal-cancer
#8
JOURNAL ARTICLE
Gozde Kavgaci, Omer Dizdar, Suayib Yalcin
Colorectal cancer (CRC) ranks third in global cancer prevalence, with 40% presenting as metastatic colorectal cancer (mCRC). KRAS mutations in mCRC patients confer resistance to anti-EGFR treatments. Promising inhibitors such as sotorasib and adagrasib targeting KRASG12C mutations have demonstrated efficacy. Herein, we present a heavily pretreated mCRC case with a progression-free survival of 12 months with sotorasib and panitumumab. In 2017, a 27-year-old male presented with abdominal pain and received a diagnosis of stage IIIC KRAS G12C mutant CRC...
March 5, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38410975/the-efficacy-and-safety-of-adding-anlotinib-in-gradual-progression-on-third-generation-egfr-tkis-for-egfr-mutant-advanced-nonsmall-cell-lung-cancer
#9
JOURNAL ARTICLE
Hai Xiang, Ding Danna, Chen Xuefei, Jinkai Zhao, Guangjun Jin
Acquired resistance is unavoidable with the approval of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for first-line therapy of advanced non small cell lung cancer (NSCLC). Some studies have found that combining antiangiogenesis medicines with EGFR-TKI may benefit clinical outcomes in EGFR-mutant NSCLC. However, it is unclear whether EGFR-TKI paired with antiangiogenesis therapy could further improve survival for patients with gradual progression. Thus, we comprised the clinical effectiveness and safety of continuous EGFR-TKI in combination with anlotinib and EGFR-TKI alone in patients who had gradual progression on third-generation EGFR-TKI treatment...
February 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38386312/venetoclax-combined-with-decitabine-induced-tumor-lysis-syndrome-in-a-young-patient-with-acute-myeloid-leukemia-a-case-report-and-literature-review
#10
JOURNAL ARTICLE
Hongyong Zhang, Jingdi Liu, Qiuling Wu, Linghui Xia
Venetoclax, in combination with hypomethylation agents (HMAs), is a novel treatment for leukemia patients with low chemotherapy tolerance. However, it has been reported to be a risk of causing tumor lysis syndrome (TLS) in chronic lymphocytic leukemia (CLL) and elderly acute myeloid leukemia (AML) patients. Here we report a rare case of a young adult AML patient who induced TLS after receiving a combination therapy of venetoclax with decitabine (DEC). A 36-year-old male patient presented with an unexplained fever and was diagnosed with AML-M5a...
February 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38386130/nfatc2-promotes-lactate-and-m2-macrophage-polarization-through-usp17-in-lung-adenocarcinoma
#11
JOURNAL ARTICLE
Liang Wang, Yuanyuan Ma, Shanyuan Zhang, Yue Yang, Bo Huang
It is well known that immune cells including macrophages within the tumor microenvironment play an essential role in tumor progression. Here, we studied how NFATc2 regulated macrophage properties in lung adenocarcinoma. Higher expression of NFATc2 was observed in the lung adenocarcinoma tissues than in the normal lung tissues. Positive relationships were found between NFATc2 and genes associated with hypoxia and glycolysis in lung adenocarcinoma from the TCGA dataset. According to single-cell sequence data, NFATc2 was closely associated with infiltrating immune cells and was related to macrophage polarization...
February 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38386015/diagnostic-and-prognostic-value-of-serum-soluble-b7-h3-in-nonsmall-cell-lung-cancer
#12
JOURNAL ARTICLE
Yinpeng Li, Leiqian Xu, Jing Li, Qian Wang, Jiao Ma
The aim of this study was to investigate the utility of serum soluble B7-H3 (sB7-H3) as a diagnostic marker for early-stage nonsmall cell lung cancer (NSCLC) and its potential for evaluating the prognosis of patients with advanced-stage NSCLC. In this study, an ELISA was employed to detect the expression levels of sB7-H3 in a cohort of patients diagnosed with NSCLC (n = 122) and a control group (n = 42) during the same observation period. Comparative analyses were conducted to ascertain the variations in sB7-H3 concentrations between the NSCLC cohort and the healthy control group, as well as across pathological types and the presence and absence of lymph node metastasis...
February 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38386011/plasma-spd-l1-and-vegf-levels-are-associated-with-the-prognosis-of-nsclc-patients-treated-with-combination-immunotherapy
#13
JOURNAL ARTICLE
Changhong Dong, Kaiyuan Hui, Jie Gu, Mei Wang, Chenxi Hu, Xiaodong Jiang
The clinical significance of plasma soluble programmed cell death ligand 1 (sPD-L1) and vascular endothelial growth factor (VEGF) for non-small cell lung cancer (NSCLC) treated with the combination of anti-angiogenic therapy and anti-PD-L1 antibody (Ab) remain unknown. This study aimed to explore the association between plasma sPD-L1 and VEGF levels and the prognosis of NSCLC patients treated with the combination of Envafolimab and Endostar. Peripheral blood samples were collected from 24 NSCLC patients at baseline and after 6 weeks of treatment and were detected for sPD-L1 and VEGF levels...
February 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38385998/anlotinib-plus-sintilimab-achieved-in-an-antitumor-effect-of-complete-remission-in-a-patient-with-advanced-hepatocellular-carcinoma-a-case-report
#14
JOURNAL ARTICLE
Caiping Sun, Xiaoteng Ma, Liming Jiang, Xiaoling Zhu
Systemic therapies-based combination treatments have been developed rapidly in patients with advanced hepatocellular carcinoma (HCC). However, there are still a few patients not applicable to any recommended therapies, making it considerable to try new therapeutic options. Among them, anlotinib, a new oral tyrosine kinase inhibitor, is being widely used for many advanced malignancies. We present the first case of the antitumor effect of complete remission by anlotinib combined with an anti-programmed cell death protein 1 antibody, sintilimab, in a patient with advanced HCC...
February 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38385995/neoadjuvant-savolitinib-targeted-therapy-for-stage-iiib-n3-lung-adenocarcinoma-harboring-mesenchymal-epithelial-transition-exon-14-skipping-mutation-a-case-report-and-literature-review
#15
JOURNAL ARTICLE
Lei Chen, Jin-Feng Chen, Jin-Tao He, Hao Rong, Xiang Zhuang, Jun Peng
Savolitinib is a selective inhibitor that specifically targets the phosphorylation of mesenchymal-epithelial transition (MET) kinase. It has demonstrated significant inhibitory effects on the proliferation of tumor cells with METex14 skipping mutation, making it a promising treatment option. While it is the first approved small-molecule inhibitor specifically targeting MET kinase in China, there is limited information about its efficacy as neoadjuvant therapy for patients with supraclavicular lymph node metastasis (N3)...
February 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38385960/urinary-exosomal-mrna-as-a-biomarker-for-the-diagnosis-of-bladder-cancer
#16
JOURNAL ARTICLE
Xinying Wang, Dianbin Song, Baoxing Zhu, Yang Jin, Caisen Cai, Zhiyong Wang
OBJECTIVE: To study the diagnostic value of mRNA expression in urinary exocrine body in bladder cancer. METHODS: From February 2022 to December 2022, 60 patients diagnosed with bladder cancer by pathology in the Department of Urology, Affiliated Hospital of Chengde Medical University were selected as the case group. In total, 40 healthy subjects receiving physical examinations were selected as the control group. 100 mL of morning urine samples were collected from the subjects in both groups based on the same standard...
February 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38277337/stk214947-a-novel-indole-alkaloids-inhibits-hela-and-sk-hep-1-cells-survival-and-emt-process-by-bloking-the-notch3-and-akt-signals
#17
JOURNAL ARTICLE
Zihan Xu, Yuxin Yuan, Jiaqi Liu, Caijing Li, Kejin Chen, Fang Wang, Ganpeng Li
Apoptosis and epithelial-to-mesenchymal transition (EMT) are closely associated with tumor survival and metastasis. These are the basic events in tumor occurrence and progression. STK214947 is an indole alkaloid with a skeleton that is similar to that of indirubin. Indole alkaloids have attracted considerable attention because of their antitumor activity. However, the relationship between STK214947 and these basic events remains unknown. In this study, the effects of STK214947 on inducing apoptosis and reversing the EMT process in tumor cells were confirmed...
January 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38271682/experience-with-pembrolizumab-in-a-renal-transplant-patient-with-advanced-lung-cancer-a-case-report-and-review
#18
JOURNAL ARTICLE
Laura Fernández Madrigal, Victoria García Samblásand, Laura Sánchez Escudero
The treatment of non-small cell lung cancer (NSCLC) has undergone a change due to the advancement of new therapies, like immune checkpoint inhibitors (ICIs), including pembrolizumab. A 64-year-old woman received a kidney transplant in 2012 due to chronic kidney disease secondary to glomerulosclerosis, diagnosed in 2020 with stage IV NSCLC due to metastasis in the contralateral lung, with PD-L1 expression of 98%, starting treatment with ICIs, despite presenting a graft rejection risk around 40%. After 3 ICI cycles, the patient presented a partial response, with good tolerance to treatment and no signs of graft failure...
January 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38241197/comparison-of-effects-of-tamoxifen-and-toremifene-on-hepatic-function-and-serum-lipids-in-breast-cancer-patients-during-adjuvant-endocrine-therapy
#19
JOURNAL ARTICLE
Wenxia Wang, Xiao'an Liu
To investigate the effects of tamoxifen (TAM) and toremifene (TOR) on hepatic function and serum lipid levels in breast cancer patients receiving adjuvant endocrine therapy. The clinical data of 597 early breast cancer patients treated at the First Affiliated Hospital of Nanjing Medical University between January 2016 and December 2022 were collected. All the patients received standard adjuvant endocrine therapy with TAM or TOR after chemotherapy. Hepatic function and serum lipid data of all patients before and at 6 months and 1, 2, and 3 years after the treatment were collected retrospectively and analyzed statistically...
January 22, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38241195/m6a-methylation-of-fkfb3-reduced-pyroptosis-of-gastric-cancer-by-nlrp3
#20
JOURNAL ARTICLE
Wanyuan Chen, Xiaolin Ye, Yun Chen, Tongwei Zhao, Hongying Zhou
Gastric cancer is a kind of malignant tumor that seriously endangers human life and health. Its incidence rate and mortality rate are among the highest in the global malignant tumors. Therefore, this study explored the role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in the progression of gastric cancer and its underlying mechanism. Patients with gastric cancer were collected, and human GC cell lines (stomach gastric carcinoma 7901, stomach gastric carcinoma 823 , human gastric carcinoma cell line 803 and adenocarcinoma gastric stomach) were used in this study...
January 22, 2024: Anti-cancer Drugs
journal
journal
30611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.